Scholar Rock has won FDA approval for ISEMBYLD (apitegromab-mstn), a myostatin inhibitor the agency calls the first therapy to directly target muscle loss in spinal muscular atrophy (SMA). The Cambridge, Massachusetts company announced the approval on 11 September 2026, nineteen days ahead of its target decision date and a year after a manufacturing-related setback nearly derailed the launch.
From a Catalent inspection to a September approval
Scholar Rock’s path to a second act on Nasdaq
- May 2018
Nasdaq listing
Initial public offering priced at $14.00 a share, raising approximately $77.8 million in net proceeds under the ticker SRRK.
- September 2025
Complete Response Letter
FDA declines to approve the original apitegromab application, citing manufacturing and inspection findings at a third-party fill-finish facility — not the SAPPHIRE efficacy or safety data.
- March 2026
Resubmission
Following a positive Type C meeting with FDA, Scholar Rock resubmits the application with a second, U.S.-based fill-finish facility added to the manufacturing plan.
- 11 September 2026
FDA approval
ISEMBYLD approved nineteen days ahead of its 30 September target action date.
- September 2026
U.S. launch
Scholar Rock says commercial supply is ready and product begins shipping within days of approval.
What ISEMBYLD adds, and to whom
Scholar Rock’s approval covers ISEMBYLD for SMA patients 2 years of age and older who are currently receiving an SMN2-targeted treatment — nusinersen (Spinraza), risdiplam (Evrysdi), or, by the label’s logic, patients previously treated with onasemnogene abeparvovec (Zolgensma) who remain on an SMN2 drug. Rather than boost the SMN protein those therapies target, apitegromab inhibits latent myostatin and promyostatin, the precursors of a protein that normally limits skeletal muscle growth. FDA’s own approval announcement calls it the first therapy to directly target muscle loss in SMA.
Dosing is 10 mg/kg by intravenous infusion once every four weeks, administered over roughly 60 to 120 minutes at a rate no greater than 150 mL per hour. The most common adverse reactions reported were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis and pharyngitis; the label also notes an increased risk of fractures, reported in 9% of patients on the approved dose versus 2% on placebo in the trial.
“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.” David L. Hallal, Chairman and Chief Executive Officer, Scholar Rock — 11 September 2026 announcement
SAPPHIRE in four numbers
Figures from Scholar Rock’s SAPPHIRE trial results and 11 September 2026 announcement.
A myostatin brake, not a splicing fix
Three things that set ISEMBYLD apart
Adds onto, not instead of
ISEMBYLD is the first SMA therapy built to layer on top of an SMN2-targeted drug rather than compete with it, giving prescribers a combination option instead of a switch decision.
A monthly infusion, not a spinal tap
Dosed intravenously once every four weeks, a different administration pattern from Spinraza’s intrathecal injections or Evrysdi’s daily oral liquid.
A manufacturing stumble, not a science one
The 2025 Complete Response Letter traced to a third-party fill-finish facility, not the SAPPHIRE data; Scholar Rock resubmitted with a second U.S. site and cleared FDA ahead of its own target date.
The $10 billion SMA market ISEMBYLD joins
SMA has been a multi-drug market since Spinraza’s 2016 approval, followed by Zolgensma’s one-time gene therapy in 2019 and Evrysdi’s oral option in 2020. ISEMBYLD does not aim to unseat any of them; because the label requires an existing SMN2-targeted therapy, its addressable population is defined by how many of those patients a physician judges could gain further motor function from a second mechanism.
Spinal muscular atrophy treatment, sized to 2030
$5.89B → $10.38B
Global SMA treatment market, 2026 to 2030, as forecast by The Business Research Company (2026 report).
Sources: The Business Research Company, Spinal Muscular Atrophy Treatment Global Market Report 2026
Regulatory News outlook
We expect ISEMBYLD to add a meaningful slice on top of the existing SMN2-drug market rather than divert spending from it, since the drug is designed to be layered onto Spinraza, Evrysdi or post-Zolgensma care rather than replace any of them.
How we got here: The Business Research Company’s own forecast already implies about $4.5 billion of SMA-market growth between 2026 and 2030; because apitegromab is an add-on rather than a substitute therapy, we treat that growth as the floor for how much of the increase ISEMBYLD-eligible add-on spending could represent, not a ceiling.
Four mechanisms, one disease
| Product | Mechanism | Route | U.S. approval |
|---|---|---|---|
| ISEMBYLD (Scholar Rock) | Myostatin inhibitor; add-on to an SMN2-targeted therapy | IV infusion, once every 4 weeks | September 2026 |
| Spinraza (Biogen/Ionis) | Antisense oligonucleotide; promotes SMN2 exon-7 inclusion | Intrathecal injection | December 2016 |
| Evrysdi (Roche/PTC Therapeutics) | Small-molecule SMN2 splicing modifier | Oral, once daily | August 2020 |
| Zolgensma (Novartis) | AAV9 gene therapy delivering a functional SMN1 copy | One-time IV infusion | May 2019 |
From each company’s own labelling and announcements; not a clinical comparison. Zolgensma is approved only for patients under 2 years old with bi-allelic SMN1 mutations.
The 34.2 percent Scholar Rock needs to hold
The commercial case for ISEMBYLD rests on convincing prescribers that a second mechanism, layered onto a drug already working, is worth a monthly infusion and an estimated list price of roughly $310,000 a year. The SAPPHIRE responder analysis — 34.2% of apitegromab patients reaching a 3-point HFMSE gain against 13.5% on placebo — is the figure Scholar Rock will need payers and physicians to keep believing as real-world use replaces trial conditions.
- Launch: commercial supply was reported ready at approval, with shipping beginning within days.
- Designations: apitegromab carries FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations.
- Dosing population: approved for ages 2 and up, with no upper age limit stated, provided the patient is already on an SMN2-targeted therapy.
- Not yet public: Scholar Rock has not disclosed specific payer coverage decisions or formulary placement; the company’s patient-support program is intended to help navigate insurance during the early launch.
Sources & further reading
- Scholar Rock, “FDA Approves ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy (SMA), Marking a New Milestone in SMA Treatment,” press release, 11 September 2026. globenewswire.com
- U.S. Food and Drug Administration, “FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy.” fda.gov
- Jason Mast, “Scholar Rock wins FDA approval for first drug to target SMA muscle loss,” STAT News, 11 September 2026. statnews.com
- “Scholar Rock SMA drug approved by FDA,” BioPharma Dive, September 2026. biopharmadive.com
- Scholar Rock investor relations — news releases. investors.scholarrock.com
- The Business Research Company, “Spinal Muscular Atrophy Treatment Global Market Report 2026.” researchandmarkets.com
- Scholar Rock, “Scholar Rock Announces Pricing of Initial Public Offering,” 24 May 2018. globenewswire.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA approve for Scholar Rock?
ISEMBYLD (apitegromab-mstn), a myostatin inhibitor for spinal muscular atrophy (SMA) in adults and children 2 years and older who are currently receiving an SMN2-targeted treatment such as nusinersen or risdiplam. FDA approved it on 11 September 2026, describing it as the first therapy to directly target muscle loss in SMA.
Does ISEMBYLD replace existing SMA drugs?
No. The label requires patients to already be on an SMN2-targeted therapy; ISEMBYLD is dosed alongside it, not instead of it. It works by inhibiting myostatin, a protein that limits muscle growth, rather than by increasing the SMN protein those other drugs target.
What did the SAPPHIRE trial show?
In a 156-patient, placebo-controlled Phase 3 trial of SMA types 2 and 3, patients on the approved 10 mg/kg dose gained 2.2 points more on the Hammersmith Functional Motor Scale Expanded than placebo at 12 months, and 34.2% reached a clinically meaningful 3-point gain versus 13.5% on placebo.
Why did approval take longer than the original target?
FDA issued a Complete Response Letter in September 2025 over manufacturing and inspection findings at a third-party fill-finish facility, not over the trial data. Scholar Rock resubmitted the application in March 2026 with a second U.S. fill-finish site, and FDA approved it 11 September 2026, ahead of a 30 September target date.
